Renovaro announces expedited trial on suit to enforce Predictive Oncology merger

Renovaro (RENB) has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, in the Delaware Court of Chancery against Predictive Oncology (POAI), seeking to enforce a binding merger agreement executed on January 1. According to the Verified Complaint, the companies entered into a legally binding Letter Agreement pursuant to which Predictive Oncology would merge into Renovaro in exchange for a newly created class of preferred stock. Following the public disclosure of the agreement in a Form 8-K filed by POAI on January 6, POAI’s stock price rose by more than 50%. Renovaro alleges that Predictive Oncology breached the agreement’s exclusivity and good faith negotiation provisions by conducting a public offering of $545,000 in securities on February 19 -despite contractual restrictions-and later attempting to terminate the agreement unilaterally on April 3, without engaging meaningfully in the negotiation of a definitive merger agreement.